louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04167943: Conservative Pulp Therapy of Primary Molars Using TheraCAL
Official title: Indirect Pulp Capping, Direct Pulp Capping, Partial Pulpotomy, Pulpotomy of Primary Molars Using TheraCal; A Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Reversible Pulpitis
Keywords: indirect pulp capping
direct pulp capping
partial pulpotomy
pulpotomy
TheraCal
primary molars
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-11-19
Enrollment: 216
Sex: ALL
Minimum age (years): 4
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a clinical trial that assesses the clinical and radiographic success rates of 3 conservative pulp therapy treatments in primary molars compared to conventional pulpotomy using a bioactive dual cured calcium silicate cement (TheraCAL PT).

Detailed description: Participating Children will be recruited from the outpatient's clinic of pediatric dentistry department , Faculty of Dentistry Ain Shams University and will be allocated to one of the following groups; Indirect pulp capping, direct pulp capping, partial pulpotomy or pulpotomy. TheraCAL PT, a dual cured tricalcium silicate cement will be used in all groups as the pulp capping material. Children will be followed every 6 months for a period of 1 year to evaluate clinical and radiographic success.

Eligibility criteria: Inclusion Criteria:

* Four to six years old healthy children
* Cooperative (frankle scale + and ++)
* With at least one vital and restorable primary molar with deep caries.

Exclusion Criteria:

* History of spontaneous pain, swelling, or sinus tract
* Pathological mobility
* pain on percussion
* Furcation or periapical radiolucency
* Internal or external pathological root resorption
* Widening of periodontal membrane space
* Discontinuity of lamina dura.

Primary outcomes:
measure: Changes in Visual and tactile clinical examination
timeFrame: every 6 months
Secondary outcomes:
measure: Change in Dental Periapical Radiographic examination
timeFrame: every 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Ain Shams University
Study officials:
affiliation: Faculty of Dentistry, Ain Sham University
name: Mariem Wassel
role: STUDY_DIRECTOR
References:
Clinical trial NCT06429943: Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study
Official title: Cerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study (PILOT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SAH (Subarachnoid Hemorrhage)
Keywords: SAH
Cerebrolysin
neuromonitoring
Lead sponsor: Pomeranian Medical University Szczecin
Sponsor class: OTHER
First posted: 2024-05-28
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is the population of patients diagnosed with SAH, treated in University Hospital no.1 in Szczecin, Poland. Mainly the patients come from the population of westerpomeranian county, but as SAH is an acute disease also patients from the whole region of Poland, treated in the Hospital were included in the study.

Brief summary: Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. In recent years, advances in surgical techniques have im-proved the mortality rate. However, there is still need for the research for the optimal possible final effect of treatment. In our study, we've decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients. We've examined the supply of neuroprotective drugs and neuromonitoring.


Eligibility criteria: Inclusion Criteria:

* age \>18 years old, diagnosis of SAH, treatment in ICU conditions

Exclusion Criteria:

* age \<18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Primary outcomes:
measure: GOS Glasgow Outcome Scale
timeFrame: 1 month
Secondary outcomes:
measure: LOS Length of Stay
timeFrame: hospitalisation time
measure: mortality
timeFrame: 1 month
Other outcomes:
Locations:
city: Szczecin
country: Poland
facility: Pomeranian Medical University, University Hospital no.1
Study officials:
References:
Clinical trial NCT04031443: Prescription Pattern and Awareness About Antibiotic Prophylaxis and Resistance
Official title: The Prescription Pattern and Awareness About Antibiotic Prophylaxis and Resistance Among Pediatric Dentists (Cross Sectional Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Antibiotic Prescription
Keywords: prescription pattern
antibiotic prophylaxis
antibiotic resistance
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-07-24
Enrollment: 378
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: dental practitioner who deal with children

Brief summary: To assess the knowledge of Pediatric dentists regarding the prescription of antibiotics, antibiotic prophylaxis and antibiotic resistance

Detailed description: Antibiotics commonly are prescribed by dentists, and the uses and abuses of these drugs should be familiar to all practicing clinicians. Antibiotics are used in dentistry for two major reasons: to control oral infection, and to prevent a bacteremia precipitated by dental manipulations from causing severe systemic sequelae.

In recent years, there has been an increasing tendency to reduce the widespread use of antibiotics for prophylactic and therapeutic purposes. This is based, both on increasing scientific evidence and enhanced professional experience. The development of resistant strains of microorganisms, doubt on the efficacy of the proposed prophylactic regimens, possible toxic and adverse reactions to antibiotics and poor compliance by patients and dentists raised questions about risks and benefits.

The American Academy of Pediatric Dentistry (AAPD) has published guidelines for antibiotic use, recognizing the increasing prevalence of antibiotic-resistant microorganisms. The guidelines are intended to provide guidance for the proper and judicious use of antibiotic therapy in the treatment of oral conditions in children.

Good knowledge about the indications of antibiotics is the need of the hour in prescribing antibiotics for dental conditions. Dental practitioners should know the protocol to be applied in their patients and should apply the most recent guidelines regarding antibiotic regimen.

Eligibility criteria: * Inclusion criteria:

  * Dental practitioner
  * Deal with children
* Exclusion criteria:

  * Undergraduate student

Primary outcomes:
measure: The prescription pattern of antibiotics among Pediatric dentists
timeFrame: 1 month
Secondary outcomes:
measure: Most common antibiotic prescribed, duration and dosage
timeFrame: 1 month
measure: Clinical conditions for which antibiotics were prescribed
timeFrame: 1 months
measure: Awareness about antibiotic prophylaxis
timeFrame: 1 month
measure: Awareness about antibiotic resistance
timeFrame: 1 month
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT05193643: Minimally Invasive Treatment of Primary Great Saphenous Vein (GSV) Insufficiency Using High Intensity Focused Ultrasound (HIFU)
Official title: Minimally Invasive Treatment of Primary Great Saphenous Vein (GSV) Insufficiency Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Single Center Prospective Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Great Saphenous Vein Insufficiency
Lead sponsor: Englewood Hospital and Medical Center
Sponsor class: OTHER
First posted: 2022-01-18
Enrollment: 20
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a one-arm, open label, prospective, single-center study. Primary objective To evaluate the feasibility of HIFU for treatment of Great Saphenous Vein using assessments of patient experience and response to treatment.

Secondary objective To assess the general safety and ablation rate outcomes following HIFU treatment of GSV


Eligibility criteria: Inclusion Criteria:

1. Candidate for venous procedure with primary GSV insufficiency involving reflux in the segment to be treated
2. CEAP-clinical classification ≥ 2
3. Physical condition allowing ambulation after the procedure.
4. Agree to comply with the Clinical investigation plan and follow-up schedule of the study
5. Targeted tissue reachable for treatment with the device - meaning between 5mm and 24mm below the skin surface.
6. Age over 22 years at the time of enrollment.
7. No acute venous thrombosis.
8. No complete or near complete deep vein post-thrombotic disease.
9. Patient has signed and understood the written informed consent.

Exclusion criteria

1. Patient is pregnant
2. Known allergic reaction to anesthetics to be used.
3. Legally incapacitated or imprisoned patients
4. Patient's vein target not clearly visible on the ultrasound images (in B mode) at the inclusion visit.
5. Patient participating in another clinical trial involving an investigational drug or device.
6. Ankle-brachial index \<7 (ABI)
7. Undergoing active anticoagulant therapy within the last 6 months
8. Diameter of the treated anatomical segment below ≤ 2mm

   -

Primary outcomes:
measure: Technical Feasibility
timeFrame: 3 months
Secondary outcomes:
measure: Ablation of venous reflux
timeFrame: 3 months
Other outcomes:
Locations:
city: Englewood
country: United States
facility: Englewood Health
state: New Jersey
Study officials:
References:
Clinical trial NCT04629638: Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women
Official title: Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Depression, Anxiety
Pregnancy Related
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-11-16
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Maternal attachment, edinburgh depression score and postpartum anxiety scale scores of 250 covid-19 positive pregnant women between the ages of 18-45 and 250 covid-negative pregnant women are compared.

Brief summary: Maternal attachment, Edinburgh depression scoring, and postpartum anxiety scale are evaluated in patients with covid-positive pregnancies in the 3rd month after birth.

Detailed description: Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale are evaluated in 250 covid-positive pregnant women in the 3rd month after birth. The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.

Eligibility criteria: Inclusion Criteria:

* covid -19 positive and negative pregnant women
* have no psychiatric illness
* not using antidepressants or antipsychotic drugs

Exclusion Criteria:

* women with psychiatric illness
* using antidepressants or antipsychotic drugs
* not pregnant
* adolescent pregnancy

Primary outcomes:
measure: Maternal attachment in SARS- cov2 positive and negative pregnant women
timeFrame: 3 months
measure: Edinburgh depression scores in in SARS- cov2 positive and negative pregnant women
timeFrame: 3 months
measure: Postpartum anxiety scale scores in in SARS- cov2 positive and negative pregnant women
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Pinar Yalcin Bahat
state: İ̇stanbul
Study officials:
References:
Clinical trial NCT06881238: Impact of Hepatitis B Virus on Inflammatory Bowel Disease
Official title: The Impact of Hepatitis B Virus Infection on the Clinical Course of Inflammatory Bowel Disease in Egyptian Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Inflammatory Bowel Disease (IBD)
Hepatitis B Virus
Keywords: Hepatitis b virus
Inflammatory bowel disease course
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-03-18
Enrollment: 162
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: IBD patients attending the Tanta Tropical Medicine Department, Faculty of Medicine.

Brief summary: The goal of this observational retrospective study is to assess the impact of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) in Egyptian patients.

Researchers will compare the IBD extent, location, severity, and behavior between IBD patients with and without HBV infection.

Participants will be subjected to history-taking (history of hospital admission and disease flare, surgical history, medication history, follow-up duration, and mortality), clinical examination, laboratory investigations, abdominal ultrasonography, and endoscopic examination.


Eligibility criteria: Inclusion Criteria:

* Male or female patients older than 18 years.
* Patients with IBD are diagnosed by clinical, radiological, endoscopic, and histological criteria.

Exclusion Criteria:

* Patients aged \< 18 years
* Unwilling to participate in our study

Primary outcomes:
measure: Number of patients with severe IBD measured by Truelove-Witts severity index
timeFrame: through study completion, an average of 6 month
measure: Hospital admission rates in IBD patients
timeFrame: through study completion, an average of 6 month
measure: number of IBD patients undergoing surgical treatment
timeFrame: through study completion, an average of 6 month
Secondary outcomes:
measure: Disease flares rates in IBD patients
timeFrame: through study completion, an average of 6 months
measure: mortality rates in IBD patients
timeFrame: through study completion, an average of 6 months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University Hospitals
state: Gharbyea
Study officials:
affiliation: Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
name: Nabila A Elgazzar, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00643838: Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers
Official title: Sedation Faisability by Inhalation of Kalinox 170 Bar During Therapeutic Cares in Primary Care Dental Centers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dental Cares
Lead sponsor: Air Liquide Santé International
Sponsor class: INDUSTRY
First posted: 2008-03-26
Enrollment: 480
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A 50% nitrous oxide / 50% oxygen premix is administrated to the patient during the realization of dental cares. This openly clinical trial is done in 36 French primary care dental centers, especially on anxious and phobic patients but also on infants or mental deficient adults. At least 480 patients will be included in this clinical protocol.


Eligibility criteria: Inclusion Criteria:

* anxious and/or phobic patients having a vomiting reflex
* very young children requiring selective dental cares
* mental deficient patient
* patient having specific phobia linked to the dental care to be done
* patient from 1 year old
* ASA 1 or ASA 2 patient
* existing of efficient contraception

Exclusion Criteria:

* ASA 3 or ASA 4 patient
* patient already treated without using Kalinox's sedation
* patient already included in this protocol in a delay lower than 7 days
* contraindication linked to the experimental product
* Kalinox's inhalation duration higher than 1 hour
* pregnant or breast-feeding women

Primary outcomes:
measure: Pain measurement by using Visual Analog Scale (VAS) and Face Pain Scale (FPS)
timeFrame: At the end of the dental care
Secondary outcomes:
measure: Patient's acceptance and doctor's satisfaction
timeFrame: At the end of dental care
Other outcomes:
Locations:
city: France
country: France
facility: Primary dental care centers
Study officials:
References:
Clinical trial NCT05399238: Thermography and Burning Mouth Syndrome
Official title: Thermography as a Non-ionizing Quantitative Tool for Diagnosing of Burning Mouth Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Burning Mouth Syndrome
Lead sponsor: Universidad de Murcia
Sponsor class: OTHER
First posted: 2022-06-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Burning mouth syndrome (BMS )patients and control healthy patients

Brief summary: Medical thermography is a noninvasive technique that allows an examiner to visualize and estimate the temperature of the body . This technique allows for an evaluation of the functionality of the structures, which is why it is considered a physiological test and records the variation in the surface temperature of the human body based on the infrared radiation emitted by the surface of that body .Subjects with burning mouth syndrome (BMS) have altered sensitivity and pain thresholds for thermal stimuli compared to a control group An objective of this study is to standardize temperature values derived from thermograms of the tongue in BMS .

Detailed description: An objective of this study is to standardize temperature values derived from thermograms of the tongue in BMS

Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations. During the tests, infrared thermal images were taken immediately after subjects protruded their tongues forward and downward to the desired position

Eligibility criteria: Inclusion Criteria:

* Written informed consent signed he patients were diagnosed with BMS according to the criteria of the International Classification of Headache Disorders

Exclusion Criteria:

* Fibromyalgia
* Fever
* Reflux
* Cancer,
* Oral infection,
* Pregnant or breastfeeding women

Primary outcomes:
measure: Measurement of temperature tongue
timeFrame: Day 1am . experimental subject and each control subject will be seen once for the administration of the thermography imagery
Secondary outcomes:
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Pia Lopez Jornet
Study officials:
References:
citation: Lv C, Wang X, Chen J, Yang N, Fisk I. A non-invasive measurement of tongue surface temperature. Food Res Int. 2019 Feb;116:499-507. doi: 10.1016/j.foodres.2018.08.066. Epub 2018 Aug 25.
citation: Mo X, Zhang J, Fan Y, Svensson P, Wang K. Thermal and mechanical quantitative sensory testing in Chinese patients with burning mouth syndrome--a probable neuropathic pain condition? J Headache Pain. 2015;16:84. doi: 10.1186/s10194-015-0565-x. Epub 2015 Sep 24.
Clinical trial NCT05405738: Cleft Palate Technique and Maxillary Growth
Official title: Effect of 2 Flap Palatoplasty Versus Furlow With Buccinators Flap During Palatal Cleft Repair on the Maxillary Development Patterns in Comparison to Non-cleft Children at 5-6years of Age
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cleft Palate
Growth
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2022-06-06
Enrollment: 28
Sex: ALL
Minimum age (years): 5
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 5-6ys old child with treated cleft palate

Brief summary: comparison of the maxillary growth between cleft palate patients that underwent to repair by 2 flap palatoplasty versus Furlow with buccinator technique


Eligibility criteria: Inclusion Criteria:

* 5-6 years old childreen with previous treated complete cleft lip and palate, nonsyndromic.
* lip and palate repair performed by one craniofacial surgeon

Exclusion Criteria:

* Patients with syndromic cleft lip.
* Redu cases
* Bilateral cleft lip
* Patient older 6years or younger 5 years.
* Associated Cardiac anomalies.
* Any systemic condition

Primary outcomes:
measure: maxillar growth
timeFrame: through study completion, an average one week
Secondary outcomes:
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: Fayoum University
Study officials:
References:
Clinical trial NCT02075138: Grass Observational Study
Official title: An Observational Multi-Centre Field Study to Assess Symptom Scores and Allergy Medication Usage in Subjects With a History of Grass-Induced Rhinoconjunctivitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Grass Allergy
Rhinoconjunctivitis
Lead sponsor: Circassia Limited
Sponsor class: INDUSTRY
Collaborators: name: Syneos Health
name: CIDAL
First posted: 2014-03-03
Enrollment: 109
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with a history of Grass induced Rhinoconjunctivitis

Brief summary: Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans, including asthma, allergic rhinitis, conjunctivitis and dermatitis.

The purpose of the current study is to evaluate allergy symptoms and allergy medication in subjects with grass-related rhinoconjunctivitis.


Eligibility criteria: Inclusion Criteria:

* History of moderate to severe rhinoconjunctivitis consistent with allergy to grass for at least 2 years.
* Forced Expiratory Volume in 1 Second (FEV1) of at least 70% of predicted value or personal best if available at the Screening Visit.
* Perennial Rye grass or Timothy grass-specific IgE ≥ 0.35 kU/L as measured by ImmunoCAP®.
* Positive skin prick test to Perennial Rye grass or Timothy grass allergen

Exclusion Criteria:

* Positive skin prick test ≥ 5 mm to any confounding, co-existing seasonal allergens likely to be present during the pre-season baseline and grass pollen period.
* Medical records of symptomatic perennial allergic rhinitis and/or asthma or a positive skin test ≥ 5 mm due to a perennial allergen to which the subject is regularly exposed (moulds, dust mites, cockroaches, and animal dander) and which cannot be avoided during the course of the study.
* Previous immunotherapy treatment with any grass allergen for more than 1 month within 5 years prior to screening.
* Subjects who had been treated with any non-grass licensed allergen immunotherapy extracts or non-grass investigational immunotherapy for more than 1 month within 1 year.

Primary outcomes:
measure: To evaluate Total Rhinoconjunctivitis Symptom Score and allergy medication use as a combine score
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
state: District of Columbia
city: Normal
country: United States
state: Illinois
city: Sylvania
country: United States
state: Ohio
city: Medford
country: United States
state: Oregon
city: Spokane
country: United States
state: Washington
city: Buenos Aires City
country: Argentina
state: Buenos Aires
city: Temuco
country: Chile
state: Araucanía
Study officials:
References: